Needham & Company Maintains a 'Buy' on NPS Pharmaceuticals (NPSP); Slight Gattex Delay Risk, Other Opportunities Underappreciated
Tweet
Share
E-mailGet Alerts NPSP Hot Sheet
Price: $45.97 --0%
Rating Summary:
8 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Rating Summary:
8 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 21 | New: 20
Join SI Premium – FREE
Needham & Company maintains a 'Buy' on NPS Pharmaceuticals Inc. (NASDAQ: NPSP).
Analyst, Alan Carr, said, "The PDUFA date for Gattex in Short Bowel Syndrome is 9/30/12. Although we are favorably inclined towards approval in the U.S., there is a risk of delayed response from the FDA. The regulatory agency has reportedly indicated to the company that an Advisory Committee meeting would likely be needed, but one has not yet been scheduled. The next available date for a Gastrointestinal Drugs AdCom meeting is 10/15/12...We are overall favorably inclined towards the stock, noting a ~$6000M EV. We believe commercial opportunities in SBS and hypoparathyroidism may be underappreciated."
For an analyst ratings summary and ratings history on NPS Pharmaceuticals Inc. click here. For more ratings news on NPS Pharmaceuticals Inc. click here.
Shares of NPS Pharmaceuticals Inc. closed at $8.85 yesterday.
Analyst, Alan Carr, said, "The PDUFA date for Gattex in Short Bowel Syndrome is 9/30/12. Although we are favorably inclined towards approval in the U.S., there is a risk of delayed response from the FDA. The regulatory agency has reportedly indicated to the company that an Advisory Committee meeting would likely be needed, but one has not yet been scheduled. The next available date for a Gastrointestinal Drugs AdCom meeting is 10/15/12...We are overall favorably inclined towards the stock, noting a ~$6000M EV. We believe commercial opportunities in SBS and hypoparathyroidism may be underappreciated."
For an analyst ratings summary and ratings history on NPS Pharmaceuticals Inc. click here. For more ratings news on NPS Pharmaceuticals Inc. click here.
Shares of NPS Pharmaceuticals Inc. closed at $8.85 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- NANO Nuclear Announces Participation in Several Investor Conferences
- TSS Inc (TSSI) PT Lowered to $13 at Needham
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
